Assessing whether the wrong young women are receiving Pap tests?

Article

According to self-reported information from young women aged 15 to 24 years, about 14% of those who have never had sexual intercourse received a Papanicolaou (Pap) test during the previous year, and about one-third of those who reported being sexually active did not.

According to self-reported information from young women aged 15 to 24 years, about 14% of those who have never had sexual intercourse received a Papanicolaou (Pap) test during the previous year, and about one-third of those who reported being sexually active did not.

The findings come from a recent analysis of survey data from 2,513 young women. Of the 33% of women who reported never having had sex, 13.9% reported having received a Pap smear in the previous year.

Of the women who reported being sexually active, 67% reported receiving a Pap smear during the previous year, and slightly more than half (59%) of the women who reported having initiated sexual activity in the previous 3 years reported receiving a Pap smear in the previous year.

If the findings in the study can be extrapolated to the population at large and if the patterns observed therein persist, the authors concluded, then education is urgently needed to ensure that Pap smears are being performed on the appropriate young women.

Saraiya M, Martinez G, Glaser K, Kulasingam S. Pap testing and sexual activity among young women in the United States. Obstet Gynecol. 2009;114(6):1213-1219.

Recent Videos
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Lauren Streicher, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.